Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The latest news, stories and exciting findings from across the Oxford cancer research community

University's RadCam library highlighted in yellow

Funding to compare imaging modalities for liver cancer detection

The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.

Ultrasensitive detection of p53 cancer biomarker

Professor Jason Davis and team have developed a new sensor to selectively and quantitatively measure p53 autoantibodies in the blood, levels of which are raised in a broad range of cancers.

Research team receives $25m Cancer Grand Challenges award

A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the solid tumours in children challenge.

AI reveals prostate cancer is not just one disease

Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer which could revolutionise how the disease is diagnosed and treated in the future.

OCION Funding Scheme: In conversation with Alistair Easton

The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardee, Alistair Easton, to discuss what research the fund will enable him to carry out.

CRUK funding success for Audrey Gérard

Audrey Gérard has received £ 1.5 million in funding from CRUK for a new research project to unravel the coevolving cancer and immune landscape.

New study provides framework for optimising the design of antibody therapeutics

New research has uncovered how antibodies trigger immune receptors in T cells. This breakthrough provides an improved framework for designing therapeutic antibodies, which could be used in new and better therapies for cancer and autoimmune diseases.

Crowd-sourcing approach assesses current methods for improved automated detection and boundary mapping of colorectal cancer precursors

A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.

World Cancer Day: Oxford University professors on the record with their contribution to the fight against cancer

Principal Investigators at the University talk candidly about their work and how they’re helping the fight against cancer.

AI-based method provides insights for predicting colorectal cancer outcomes

The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.

Patient and Public Involvement and Engagement: Working together to improve Cancer Care by Sue Duncombe

Sue Duncombe shares her experience of Patient and Public Involvement and Engagement. After her husband died of prostate cancer, Sue wanted to support research in the hope other families wouldn't experience the same loss.

Study assesses long-term risk of invasive breast cancer after pre-invasive disease

Women who are diagnosed with ductal carcinoma in situ (DCIS) outside the NHS breast screening programme are around four times as likely to develop invasive breast cancer and to die from breast cancer than women in the general population, finds new study published by The BMJ.

First patient recruited to MILI trial

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome has opened to recruitment

OCION Funding Scheme: In conversation with Kim Midwood

The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardee, Kim Midwood, to discuss what research the fund will enable her to carry out.

Challenges for colorectal cancer risk stratification in people with IBD using histology

A team of pathologists were unable to validate a histology-based assessment of cancer risk in people with inflammatory bowel disease (IBD).

Oxford Centre for Early Cancer Detection Symposium 2023 – a recap

On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE’s research in the past year and to discuss ideas for future projects.

Oxford University Hospitals launches new mRNA cancer vaccine trial for patients with head and neck cancers

The first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.

Researchers characterise the landscape of somatic mutations among acid-base transporters in human cancers

A new paper lead by Oxford Cancer DPhil student Bobby White and Professor Pawel Swietach from DPAG’s Swietach Group explores the role that somatic mutations affecting plasma membrane acid-base transporters play in human cancer evolution.

Festive Science Image Competition Winners

Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today. Three winners were selected, with the Department of Oncology's Nathalie Lovgren and Iain Tullis winning third place for their entry 'Starry Winter Night'.

Oxford Cancer Precision Prevention Symposium – a recap

To celebrate the launch of the UK’s first CRUK clinical trials unit dedicated to cancer precision prevention in Oxford, we held a research symposium that highlighted the spectra of Cancer Precision Prevention clinical programmes across the UK.

Load More